Amarin Corp Plc (AMRN)

[ggwpq]

Thanks to Dew D for posting info. on the ACCORD study yesterday.I extracted the following from the study :

"TriCor fared better in a subgroup of patients with a higher median triglyceride level of 284 and low HDL. Among those patients -- some 17 percent of participants -- the combination therapy led to about a 30-percent reduction in the risk of the composite goal of heart attack, stroke and cardiovascular death."

On Sep 25, 2013, Amarin has a press release regarding REDUCE-IT enrollment. I extracted the following from the press release :

"The active arm of the study consists of patients on optimized statin therapy plus Vascepa 4g/day. The high-risk patient population in REDUCE-IT has both a mean and median baseline triglyceride (TG) level over 200 mg/dL, a level substantially above those from recently conducted outcomes trials of other prescription lipid modifying therapies. Furthermore, Amarin has taken steps to ensure that the final baseline TG levels remain above 200 mg/dL. In addition, all patients enrolled in the study have either documented cardiovascular disease (CVD) or are at high-risk for CVD."

Intelligent investors can draw their own conclusions about the probability of success of REDUCE-IT.